Correction to Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors [Hepatology, 61, (2015), 66-76], DOI: 10.1002/hep.27381;Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors

Hepatology

Volumn 61, Issue 1, 2015, Pages 66-76

  van Bömmel, Florian ^a   Bartens, Anne ^a,b   Mysickova, Alena ^c   Hofmann, Jörg ^b   Krüger, Detlev H ^b   Berg, Thomas ^a   Edelmann, Anke ^b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROCONVERSION; SEX; TREATMENT DURATION; ADOLESCENT; BLOOD; HEPATITIS B, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; VIROLOGY; VIRUS REPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; RNA, VIRAL; VIRUS REPLICATION; YOUNG ADULT;

EID: 84920983133     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28349     Document Type: Erratum

References (23)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
3. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-1075.
4. Marcellin P, Gane EJ, Tsai N, Flisiak R, Petersen J, Gurel, et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical, and serological responses with no detectable resistance [abstrcat]. Hepatology 2013;58(Suppl):649A.
5. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194.
6. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
7. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
8. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013;20:37-46.
9. Marcellin P, Heathcote EJ, Buti M, Krastev Z, Jacobson IM, de Man RA, et al. Characterization of HBsAg Kinetics and HBsAg seroconversion in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) [abstract]. Hepatology 2011;54(Suppl):1036A.
10. Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat 2013;20:9-17.
11. Lai CL, Gane E, Liaw YF, Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
12. Su Q, Wang SF, Chang TE, Breitkreutz R, Hennig H, Takegoshi K, et al. Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res 2001;7:2005-2015.
13. Guirgis BS, Abbas RO, Azzazy HM. Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis 2010;14:941-953.
14. Hilger C, Velhagen I, Zentgraf H, Schröder CH. Diversity of hepatitis B virus X gene- related transcripts in hepatocellular carcinoma: a novel polyadenylation site on viral DNA. J Virol 1991;8:4284-4291.
15. Zhang W, Hacker HJ, Mildenberger M, Su Q, Schröder CH. Detection of HBV RNA in serum of patients. Methods Mol Med 2004;95:29-40.
16. Frohman MA, Dush MK, Martin GR. Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. PNAS 1988;85:8998-9002.
17. Kairat A, Beerheide W, Zhou G, Tang ZY, Edler L, Schröder CH. Truncated hepatitis B virus RNA in human hepatocellular carcinoma: its representation in patients with advancing age. Intervirology 1999;42:228-237.
18. Zou H, Hastie T. Regularization and variable selection via the Elastic Net. J Roy Stat Soc B 2005;67:301-320.
19. Rokuhara A, Matsumoto A, Tanaka E, Umemura T, Yoshizawa K, Kimura T, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol 2006;41:785-790.
20. Zhang W, Hacker HJ, Tokus M, Bock T, Schröder CH. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol 2003;17:24-30.
21. Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. HEPATOLOGY 2007;45:1179-1186.
22. Zhang W, Li YH, Zhu SJ, Zhang Y, Gong L, Wang SM, et al. A serum marker for early detection of resistance development during lamivudine therapy. Ann N Y Acad Sci 2008;1137:264-272.
23. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-592.